This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB06268/identifier/chemspider/
n7http://linked.opendata.cz/resource/drugbank/drug/DB06268/identifier/chebi/
n23http://bio2rdf.org/drugbank:
n22http://linked.opendata.cz/resource/drugbank/drug/DB06268/identifier/wikipedia/
n21http://linked.opendata.cz/resource/drugbank/drug/DB06268/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/patent/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n6http://linked.opendata.cz/resource/drugbank/drug/DB06268/identifier/bindingdb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB06268/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n10http://linked.opendata.cz/resource/drugbank/drug/DB06268/identifier/pubchem-substance/
n4http://linked.opendata.cz/resource/drugbank/property/
n11http://linked.opendata.cz/resource/drugbank/drug/DB06268/identifier/kegg-drug/
n16http://linked.opendata.cz/resource/drugbank/drug/DB06268/identifier/iuphar/
n18http://linked.opendata.cz/resource/drugbank/drug/DB06268/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/drugbank/drug/DB06268/identifier/guide-to-pharmacology/
n20http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06268
rdf:type
n3:Drug
n3:group
approved investigational
n3:halfLife
10 hours
n3:indication
Investigated for use/treatment in pulmonary hypertension, connective tissue diseases, hypertension, and congestive heart failure.
owl:sameAs
n13:DB06268 n23:DB06268
dcterms:title
Sitaxentan
adms:identifier
n6:50058126 n7:123417 n10:99443241 n11:D07171 n14:216235 n15:3950 n16:3950 n17:187436 n18:DB06268 n21:PA165958361 n22:Sitaxentan
n3:mechanismOfAction
Sitaxentan is a competitive antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors. Under normal conditions, endothelin-1 binding of ET-A or ET-B receptors causes pulmonary vasoconstriction. By blocking this interaction, Sitaxentan decreases pulmonary vascular resistance. Sitaxentan has a higher affinity for ET-A than ET-B.
n3:patent
n8:2161346 n8:2281090
n3:routeOfElimination
Renal (50 to 60%) Fecal (40 to 50%)
n3:synonym
Thelin Sitaxsentan Sitaxentan
n3:foodInteraction
Take without regard to meals
n3:proteinBinding
99% +
n3:IUPAC-Name
n4:271B4B81-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4B87-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4B86-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4B83-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4B84-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4B85-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4B7F-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4B7D-363D-11E5-9242-09173F13E4C5 n4:271B4B80-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4B7E-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n20:C02KX03
n3:H-Bond-Acceptor-Count
n4:271B4B8D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4B8E-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4B88-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4B89-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4B8B-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4B8A-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4B8C-363D-11E5-9242-09173F13E4C5
n3:absorption
70-100%
n3:casRegistryNumber
210421-64-0
n3:Bioavailability
n4:271B4B93-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4B95-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4B96-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4B92-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4B91-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4B94-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4B82-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4B8F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4B90-363D-11E5-9242-09173F13E4C5